SOURCE: HealthSonix, Inc.

November 01, 2006 08:00 ET

HealthSonix Files International PCT Patent Application for Its Sound Pressure Wave Technology

IRVINE, CA -- (MARKET WIRE) -- November 1, 2006 -- HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) today announced that the company has filed a Patent Cooperation Treaty (PCT) application to reserve the right to later file foreign patent applications in other key markets around the world. With this filing, future applications will be accorded the same effective filing date as the US patent application.

"The enSonix and AquaSonix line of medical products rely on our unique sound pressure wave technology which represents a medical breakthrough in the fight against the pain of arthritis. Protecting that intellectual property remains a high priority and HealthSonix will use its resources to ensure that our products receive the strongest protection possible around the world," stated Dieter Doederlein, Vice President of Corporate Development.

The Patent Cooperation Treaty (PCT) was established to provide an efficient and cost-effective way to enter into the patenting process in many different countries at one time. Most of the countries in the world are signatories to the Paris Convention. The PCT permits the filing of an "international" patent application either immediately or within one year of the filing of a patent application in any of the member nations. This filing now gives HealthSonix the ability to file for additional international patents over the next 18 months while retaining the original US priority filing date.

HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company's core offerings are based on proprietary, patent pending medical technologies that use sound pressure waves to administer sub-sensory micro vibration to the human body. Precisely formatted low frequency sound pressure waves have proven to be 80% effective in treating the pain of many diseases, particularly arthritis. All treatments and products are safe, non-invasive, drug free, and have no known side effects.

More information regarding HealthSonix and its products and services can be found at: or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

Contact Information